Alpha-v beta-3

α_Vβ₃ is a type of integrin that is a receptor for vitronectin.^[1] It consists of two components, integrin alpha V and integrin beta 3 (CD61), and is expressed by platelets. Furthermore, it is a receptor for phagocytosis on macrophages or dendritic cells.^[2]

As a drug target

Integrin α_Vβ₃ is potential drug target because abnormal expression of v3 is linked to the development and progression of various diseases.^[3]

Inhibitors like etaracizumab may be used as antiangiogenics.^[4]

One novel protein (ProAgio) has been designed to bind at an unusual site, and then induces apoptosis by recruiting caspase 8.^[3]

↑ Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D, Caspary RG, Lindberg FP, Armitage R, Maliszewski C, Delespesse G, Sarfati M (February 1999). "The vitronectin receptor and its associated CD47 molecule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23". J. Cell Biol. 144 (4): 767–75. doi:10.1083/jcb.144.4.767. PMC 2132927. PMID 10037797.
↑ Yamaguchi H, Takagi J, Miyamae T, Yokota S, Fujimoto T, Nakamura S, Ohshima S, Naka T, Nagata S (May 2008). "Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus". J. Leukoc. Biol. 83 (5): 1300–7. doi:10.1189/jlb.1107730. PMID 18303131.
1 2 Novel Protein Agent Targets Cancer and Host of Other Diseases. June 2016
↑ Santulli, Gaetano; Basilicata, Maria; De Simone, Mariarosaria; Del Giudice, Carmine; Anastasio, Antonio; Sorriento, Daniela; Saviano, Michele; Del Gatto, Annarita; Trimarco, Bruno; Pedone, Carlo; Zaccaro, Laura; Iaccarino, Guido (2011). "Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit". Journal of Translational Medicine. 9 (1): 7. doi:10.1186/1479-5876-9-7. ISSN 1479-5876.

integrin alphaVbeta3 at the US National Library of Medicine Medical Subject Headings (MeSH)

Alpha

Beta

Dimers

Cytoadhesin receptor:	Integrin alpha6beta4 Glycoprotein IIb/IIIa ITGA2B+ITGB3

Fibrinogen receptor:	Macrophage-1 antigen CD11b+CD18

Fibronectin receptor:	Integrin alpha2beta1 Integrin alpha4beta1 Integrin alpha5beta1

Leukocyte-adhesion receptor:	LFA-1 CD11a+CD18 Macrophage-1 antigen CD11b+CD18 Integrin alphaXbeta2 CD11c+CD18

Very late antigen receptor:	Integrin alpha1beta1 Integrin alpha2beta1 Integrin alpha3beta1 VLA-4 CD49d+CD29 Alpha-5 beta-1 Integrin alpha6beta1

Vitronectin receptor:	Alpha-v beta-3 Alpha-v beta-5

see also cell surface receptor deficiencies

Antiangiogenics

Endogenous	Angiopoietin 2 angiostatin canstatin calreticulin endostatin IFN-α IFN-β IFN-γ CXCL10 IL-4 IL-12 IL-18 maspin Meth-1 Meth-2 osteopontin platelet factor-4 prolactin proliferin-related protein prothrombin (kringle domain-2) antithrombin III fragment SPARC Thrombospondin 1 TIMP vasostatin VEGI soluble VEGFR-1 NRP-1 CDAI

Exogenous	2-Methoxyestradiol α_Vβ₃ inhibitors angiostatic steroids heparin angiostatin bevacizumab carboxyamidotriazole Cartilage-Derived Angiogenesis Inhibitory Factor CM101 endostatin IFN-α IL-12 itraconazole linomide matrix metalloproteinase inhibitors platelet factor-4 prolactin SU5416 suramin tasquinimod tecogalan tetrathiomolybdate thalidomide thrombospondin thrombospondin TNP-470 VEGFR antagonists

See also	Angiogenesis Angiogenesis inhibitors

This article is issued from Wikipedia - version of the 11/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.